MARKET

CELC

CELC

Celcuity Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.91
+0.41
+3.87%
Opening 10:58 08/11 EDT
OPEN
10.68
PREV CLOSE
10.50
HIGH
10.98
LOW
10.35
VOLUME
11.29K
TURNOVER
101.22K
52 WEEK HIGH
23.11
52 WEEK LOW
4.810
MARKET CAP
162.96M
P/E (TTM)
-4.3588
1D
5D
1M
3M
1Y
5Y
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that it will release its financial results for the second quarter 2022 after the stock market cl...
ACCESSWIRE · 08/04 12:15
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
/ Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced its participation in the Canaccord Genuity 42nd Annual Growth Conference to be held in Boston ...
ACCESSWIRE · 08/03 14:15
Celcuity stock soars after hours on breakthrough therapy designation for cancer drug
Shares of Celcuity Inc. were up 17% at $10.80 after hours as the U.S. Food and Drug Administration granted Breakthrough Therapy designation for a cancer drug.
marketwatch.com · 07/18 22:31
Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment
Shares of micro-cap company Celcuity (NASDAQ:CELC) <font color="gre...
Seekingalpha · 07/18 21:41
Celcuity Announced FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that the U.S.
Benzinga · 07/18 21:12
Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet
The mean of analysts' price targets for Celcuity, Inc. (CELC) points to a 359.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an ...
Zacks · 06/15 13:55
Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 461.9% in Celcuity, Inc. (CELC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might tr...
Zacks · 05/30 13:55
--Needham Adjusts Celcuity's Price Target to $25 from $50, Keeps Buy Rating
MT Newswires · 05/17 11:50
More
No Data
Learn about the latest financial forecast of CELC. Analyze the recent business situations of Celcuity Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CELC stock price target is 30.50 with a high estimate of 50.00 and a low estimate of 20.00.
High50.00
Average30.50
Low20.00
Current 10.91
EPS
Actual
Estimate
-0.89-0.67-0.44-0.22
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 70
Institutional Holdings: 5.70M
% Owned: 38.18%
Shares Outstanding: 14.94M
TypeInstitutionsShares
Increased
13
418.82K
New
6
27.86K
Decreased
16
74.96K
Sold Out
6
505.08K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
-0.08%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Brian Sullivan
Co-Founder/Chief Scientific Officer/Vice President/Secretary/Director
Lance Laing
Chief Financial Officer
Vicky Hahne
Independent Director
Richard Buller
Independent Director
David Dalvey
Independent Director
Leo Furcht
Independent Director
Richard Nigon
No Data
No Data
About CELC
Celcuity, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering cancer sub-types molecular-based approaches through developing companion diagnostic tests (CDx) and therapeutic (Rx). The Company's product pipeline includes CELsignia platform and Gedatolisib. The CELsignia diagnostic platform is used to analyze live patient tumor cells to identify the specific abnormal cellular process driving a patients cancer and the targeted therapy. The CELsignia platform provides traditional molecular diagnostics, which includes snapshot of the genetic mutations present in a patients tumor because they analyze cell fragments and molecular diagnostics can estimate the patients potential drug response based on a statistical analysis of the drugs clinical trial result. Its other product candidate includes Gedatolisib, is a small molecule dual inhibitor, administered intravenously, that targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR).

Webull offers kinds of Celcuity Inc stock information, including NASDAQ:CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.